Akihiro Matsunaga
Shinjuku, 1628655, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
COVID-19-associated large-vessel vasculitis with elevated anti-angiotensin converting enzyme 2 antibody: three cases and a review of the literature.
Journal: Clinical rheumatology
Published: September 04, 2025
Inhaled ciclesonide does not affect production of antibodies or elimination of virus in patients with COVID-19: Subanalysis of a multicenter, open-label randomized trial.
Journal: Drug discoveries & therapeutics
Published: October 29, 2023
Efficacy of convalescent plasma therapy for COVID-19 in Japan: An open-label, randomized, controlled trial.
Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
Published: February 19, 2023
Association between SARS-CoV-2 anti-spike antibody titers and the development of post-COVID conditions: A retrospective observational study.
Journal: Global health & medicine
Published: December 02, 2022
Robust protein-based engineering of hepatocyte-like cells from human mesenchymal stem cells.
Journal: Hepatology communications
Published: July 06, 2022
Long COVID: current status in Japan and knowledge about its molecular background.
Journal: Global health & medicine
Published: March 09, 2022
Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: February 24, 2022
Multisystem Inflammatory Syndrome in Adult after First Dose of mRNA Vaccine.
Journal: Emerging infectious diseases
Published: February 11, 2022
Safety of convalescent plasma therapy for COVID-19 patients and analysis of viral kinetics: A single-center, open-label, single-arm, interventional study in Japan.
Journal: GHM open
Published: February 09, 2022
Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.
Journal: Antiviral research
Published: January 28, 2022
Last Updated: 09/26/2026